

Barium Plus Food Elicits GI Symptoms on Exam

BY BRUCE K. DIXON
Chicago Bureau

CHICAGO — Adding food provocation to a standard upper GI series may better characterize alimentary tract dysfunction and guide therapy, compared with use of liquid barium alone, according to a study presented at the annual meeting of the Radiological Society of North America.

“While a food provocation study may be overkill for the typical reflux patient, it may be a useful adjunct to a standard upper GI series in patients who have severe symptoms when they eat specific foods and who have otherwise unremarkable prior exams,” Dr. Ashraf Thabet said.

He and his associates reviewed the medical records for all provocative food studies requested by surgeons and gastroenterologists that were performed from 1997 to 2005 at Massachusetts General Hospital, Boston.

The study group included 29 patients with a mean age of 56 years. All had se-



‘Of all of the patients who had no symptoms with liquid barium alone, symptoms were provoked with food in half.’

DR. THABET

vere symptoms after meals and unremarkable upper GI exams or cross-sectional imaging or gastric emptying studies, said Dr. Thabet, who is an interventional radiologist.

Patient histories detailed the food type and amount that elicited symptoms and described prior GI surgery. Symptoms caused by food ingestion included dysphagia, abdominal pain, odynophagia, nausea, vomiting, heartburn, weight loss, and recurrent aspiration. Two-thirds of the patient cohort had histories of upper GI surgery, most commonly esophagectomy, fundoplication, and gastric bypass.

The provocative food study began with a standard upper GI exam using liquid barium alone. Then the patient was asked to eat food brought from home and was re-examined fluoroscopically. The researchers looked at whether symptoms were elicited when the food was eaten and whether fluoroscopy detected an abnormality.

One 62-year-old man who had undergone esophagectomy for esophageal cancer had complained of postprandial nausea and abdominal pain. A work-up at an outside institution included negative findings from a standard upper GI barium exam and unremarkable right upper-quadrant ultrasound findings. When the patient came to Massachusetts General for a second opinion, a surgeon recommended a provocative study, Dr. Thabet said.

“The barium study produced no symptoms, but when the patient ate a muffin he developed nausea and abdominal pain, and it was observed fluoroscopically that there was a delay in propagation of food from the intrathoracic stomach distally to [the] small bowel. The patient’s surgeon

then performed an endoscopic [dilation] of the pylorus, and the patient’s symptoms improved,” he said.

Liquid barium alone reproduced symptoms in only 3 of the 29 patients; after the addition of food provocation, 2 of those 3 patients had worsening symptoms. Of the remaining 26 patients, 13 reported symptoms after food provocation.

About half of the patients (14 of 29) had a fluoroscopic abnormality (FA) with barium only. Of those 14, all but 1 had an ad-

ditional or more prominent FA with food. Of the 15 patients in whom barium alone did not result in an FA, 7 had an FA after food provocation. Abnormalities included altered peristalsis (20 patients), luminal narrowing (3), reflux alone (2), and a grapefruit-sized epiphrenic diverticulum (1).

Surgical therapy (esophagectomy, gastropasty, and fundoplication) was pursued in 40% of the patients. Endoscopic therapy (dilation and/or botulinum toxin therapy) was pursued in 20%, and 40% had

medical therapy or continued observation.

“Of all of the patients who had no symptoms with liquid barium alone, symptoms were provoked with food in half of them, and almost all of them had a fluoroscopic abnormality. Of the other 50% who had no symptoms even after food provocation, a fluoroscopic abnormality was still demonstrated in 54%,” Dr. Thabet said, adding that referring physicians appeared to be more confident about treatment decisions after a food study was performed. ■

CALLING ALL ADOLESCENTS AND ADULTS



A CALL TO ARMS
AGAINST PERTUSSIS

Pertussis protection for both adolescents and adults 11 through 64 years of age

Adacel[®]
Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular
Pertussis Vaccine Adsorbed

Arming More People Against Pertussis

Safety Information

ADACEL vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

As with any vaccine, ADACEL vaccine may not protect 100% of vaccinated individuals. There are risks associated with all vaccines. The most common injection site adverse events include pain, erythema, and swelling. The most common systemic adverse events include headache, body ache, tiredness, and fever. ADACEL vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in ADACEL vaccine should be carried out. Because any intramuscular injection can cause injection site hematoma, ADACEL vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer ADACEL vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.

Before administering ADACEL vaccine, please see brief summary of full Prescribing Information on following page.

ADACEL vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

To order ADACEL vaccine, log onto www.vaccineshoppe.com or call 1-800-VACCINE (1-800-822-2463)

Learn about pertussis disease and prevention at www.ADACELVACCINE.com

sanofi pasteur. Discovery Drive, Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
MKT11510-3R © 2006 Sanofi Pasteur Inc. 12/06 Printed in USA

sanofi pasteur
The vaccines business of sanofi-aventis Group